A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder.
Phase of Trial: Phase III
Latest Information Update: 23 Mar 2012
At a glance
- Drugs Ziprasidone (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 23 Mar 2012 Actual patient number is 61 according to ClinicalTrials.gov.
- 23 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 23 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.